RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 62 filers reported holding RA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $79,786,000 | +83.9% | 1,661,842 | +79.8% | 0.02% | +137.5% |
| Q4 2019 | $43,383,000 | +620.3% | 924,425 | +263.0% | 0.01% | +700.0% |
| Q3 2019 | $6,023,000 | -14.3% | 254,660 | +4.0% | 0.00% | 0.0% |
| Q2 2019 | $7,026,000 | +31.1% | 244,951 | +2.4% | 0.00% | 0.0% |
| Q1 2019 | $5,360,000 | +23.4% | 239,269 | +0.3% | 0.00% | 0.0% |
| Q4 2018 | $4,342,000 | -23.5% | 238,591 | -23.9% | 0.00% | 0.0% |
| Q3 2018 | $5,674,000 | +117.1% | 313,700 | +19.4% | 0.00% | 0.0% |
| Q2 2018 | $2,614,000 | +12.9% | 262,690 | -39.8% | 0.00% | – |
| Q1 2018 | $2,315,000 | -0.4% | 436,091 | +59.5% | 0.00% | – |
| Q4 2017 | $2,324,000 | -37.9% | 273,377 | +6.7% | 0.00% | -100.0% |
| Q3 2017 | $3,742,000 | -0.1% | 256,300 | +28.2% | 0.00% | 0.0% |
| Q2 2017 | $3,746,000 | +17.7% | 199,900 | +33.7% | 0.00% | 0.0% |
| Q1 2017 | $3,182,000 | +25.6% | 149,468 | -10.4% | 0.00% | 0.0% |
| Q4 2016 | $2,534,000 | – | 166,816 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |